Centauri Therapeutics Limited

Centauri Therapeutics has selected its first clinical candidate in the ABX-01 program, targeting Gram-negative bacterial infections in the lung. The lead candidate is a broad-spectrum antimicrobial peptide with a dual mechanism of action, combining immunotherapeutic effects through complement fixation and phagocytosis with intrinsic antibacterial properties. Preclinical studies have demonstrated activity against Gram-negative bacteria, with impressive survival rates in a nine-day mouse pneumonia model compared to standard of care. The company is now conducting regulatory preclinical activities to enable progression to Phase I clinical trials.